0001179110-19-003505.txt : 20190307 0001179110-19-003505.hdr.sgml : 20190307 20190307151902 ACCESSION NUMBER: 0001179110-19-003505 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190307 FILED AS OF DATE: 20190307 DATE AS OF CHANGE: 20190307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SAUNDERS BRENT L CENTRAL INDEX KEY: 0001268854 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36867 FILM NUMBER: 19665659 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD STREET 2: C/O SCHERING PLOUGH CORP CITY: KENILWORTH STATE: NJ ZIP: 07033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allergan plc CENTRAL INDEX KEY: 0001578845 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK CITY: COOLOCK, DUBLIN STATE: L2 ZIP: D17 E400 BUSINESS PHONE: (216) 523-5000 MAIL ADDRESS: STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK CITY: COOLOCK, DUBLIN STATE: L2 ZIP: D17 E400 FORMER COMPANY: FORMER CONFORMED NAME: Actavis plc DATE OF NAME CHANGE: 20130930 FORMER COMPANY: FORMER CONFORMED NAME: Actavis Ltd DATE OF NAME CHANGE: 20130607 4 1 edgar.xml FORM 4 - X0306 4 2019-03-07 0 0001578845 Allergan plc AGN 0001268854 SAUNDERS BRENT L CLONSHAUGH BUSINESS AND TECHNOLOGY PARK, COOLOCK, CO. DUBLIN L2 D17 E400 IRELAND 1 1 0 0 Chairman, President and CEO Ordinary Shares, par value $0.0001 2019-03-07 4 P 0 300 142.18 A 169206.29 D Ordinary Shares, par value $0.0001 2019-03-07 4 P 0 860 143.70 A 170066.29 D Ordinary Shares, par value $0.0001 2019-03-07 4 P 0 600 144.37 A 170666.29 D The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $142.09 to $142.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $143.13 to $143.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $144.15 to $144.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. /s/ A. Robert D. Bailey, Attorney-in-Fact for the Reporting Person 2019-03-07